+Compare
NKTX
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
68.19M

NKTX Nkarta Forecast, Technical & Fundamental Analysis

a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for NKTX with price predictions
08:00 PM EDT Sep 28, 2023

NKTX sees MACD Histogram just turned negative

NKTX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 29, 2023. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 27 instances where the indicator turned negative. In of the 27 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 28, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on NKTX as a result. In of 55 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NKTX entered a downward trend on September 29, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for NKTX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in of 152 cases, the price rose further within the following month. The odds of a continued upward trend are .

NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.214) is normal, around the industry mean (22.693). P/E Ratio (0.000) is within average values for comparable stocks, (131.605). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.099). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (304.777).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.19B. The market cap for tickers in the group ranges from 402 to 407.89B. NVO holds the highest valuation in this group at 407.89B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 18%, and the average quarterly price growth was 21%. SLNO experienced the highest price growth at 494%, while RNAZ experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was 41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

NKTX is expected to report earnings to -68 cents per share on November 08

Nkarta NKTX Stock Earnings Reports
Q3'23
Est.
$-0.69
Q2'23
Missed
by $0.03
Q1'23
Beat
by $0.04
Q4'22
Missed
by $0.05
Q3'22
Beat
by $0.02
The last earnings report on August 10 showed earnings per share of -68 cents, missing the estimate of -64 cents. With 979.17K shares outstanding, the current market capitalization sits at 68.19M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
6000 Shoreline Court
Phone
+1 905 407-1049
Employees
163
Web
https://www.nkartatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
APAAF0.110.03
+40.13%
APPIA RARE EARTHS & URANIUM CORP.
ABIT0.070.01
+23.72%
ATHENA BITCOIN GLOBAL
NPSCY7.68-0.06
-0.78%
Nippon Steel Corporation
SFTBY20.71-0.34
-1.62%
Softbank Group Corp
AGESY39.35-2.17
-5.23%
ageas SA/NV

NKTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NKTX has been loosely correlated with ACET. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NKTX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
-7.33%
ACET - NKTX
51%
Loosely correlated
-4.23%
ICCC - NKTX
43%
Loosely correlated
+1.52%
REGN - NKTX
38%
Loosely correlated
-1.35%
ICPT - NKTX
38%
Loosely correlated
-0.16%
DTIL - NKTX
37%
Loosely correlated
-4.16%
More

Groups containing NKTX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NKTX
1D Price
Change %
NKTX100%
-7.33%
biopharmaceutical
(undefined stocks)
45%
Loosely correlated
-4.51%
treatment
(undefined stocks)
37%
Loosely correlated
-2.73%
cancer
(undefined stocks)
36%
Loosely correlated
-3.16%